3-pyridin-4-yl-2,4-dihydro-indeno[1,2-.c.]pyrazole

A synthetic small molecule belonging to the pyridine and pyrazole chemical classes. It is an experimental compound with no current clinical approval or marketed indications. The molecule has been identified in cheminformatics and drug discovery databases as a potential cyclin-dependent kinase inhibitor (notably CDK2), suggesting possible utility in oncology or cell cycle-related research. There are no known approved therapeutic uses or completed clinical trials for this compound as of June 2025. Its mechanism of action is presumed to involve ATP binding inhibition at the cyclin-dependent kinase active site based on structural similarity and database annotations[1][2][6].

Other names

3-PYRIDIN-4-YL-2,4-DIHYDRO-INDENO[1,2-.C.] PYRAZOLE(2S)-1-(4-bromophenyl)-3-{[5-(3-methyl-1H-indazol–5–yl)pyridin–3–yl]oxy}propan–2–amineindazole-pyridine, 13l5-{5-[ (2S) -2-amino –3-(4-bromophenyl)propoxy ]pyridin –3 –yl } –3-methyl –1H-indazole